Activity of thalidomide in patients with platinum-refractory germ-cell tumours

European Journal of Cancer

Volumn 42, Issue 12, 2006, Pages 1775-1779

  Rick, O ^a   Braun, T ^b   Siegert, W ^b   Beyer, J ^c  

^a Klinik Reinhardshohe   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Germ cell tumour; Palliative treatment; Testicular neoplasm; Thalidomide

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; OXALIPLATIN; PACLITAXEL; PLATINUM; THALIDOMIDE; VINBLASTINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG ERUPTION; GERM CELL TUMOR; HUMAN; LETHARGY; MALE; NEUROTOXICITY; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; SALVAGE THERAPY; SENSORIMOTOR NEUROPATHY; TREATMENT FAILURE;

ADULT; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GONADAL DISORDERS; HUMANS; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; PLATINUM COMPOUNDS; THALIDOMIDE; UROGENITAL NEOPLASMS;

EID: 33746714377     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.03.013     Document Type: Article

References (9)

1. Bosl G., and Motzer R.J. Testicular germ-cell cancer. N Engl J Med 337 (1997) 242-254
2. Pont J., Bokemeyer C., Harstrick A., Sellner F., Greinix H., and Stoiber F. Chemotherapy for germ cell tumors relapsing after high-dose chemotherapy and stem cell support: a retrospective multicenter study of the Austrian Study Group on Urologic Oncology. Ann Oncol 8 (1997) 1229-1234
3. Kollmannsberger C., Schleucher N., Rick O., et al. Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support. Eur J Cancer 39 (2003) 775-782
4. Porcu P., Bhatia S., Sharma M., and Einhorn L.H. Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 18 (2000) 1181-1186
5. Kumar S., Witzig T.E., and Rajkumar S.V. Thalidomide: current role in the treatment of non-plasma cell malignancies. J Clin Oncol 22 (2004) 2477-2488
6. Fukuda S., Shirahama T., Imazono Y., et al. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 85 (1999) 1323-1330
7. Aigner A., Brachmann P., Beyer J., et al. Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol 14 (2003) 1525-1529
8. Rick O., Bokemeyer C., Beyer J., et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19 (2001) 81-88
9. National Cancer Institute. Common Toxicity Criteria v2.0 (CTC). Updated 18th August 1999. Available from http://ctep.cancer.gov.